Patents by Inventor Franziska Lechner

Franziska Lechner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180036399
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: January 17, 2017
    Publication date: February 8, 2018
    Applicant: KUROS BIOSCIENCES AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Publication number: 20180015160
    Abstract: The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.
    Type: Application
    Filed: February 24, 2017
    Publication date: January 18, 2018
    Inventors: Martin F. BACHMANN, Franziska LECHNER, Tazio STORNI
  • Publication number: 20160008453
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: November 14, 2014
    Publication date: January 14, 2016
    Applicant: CYTOS BIOTECHNOLOGY AG
    Inventors: WOLFGANG A. RENNER, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Publication number: 20150320855
    Abstract: The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.
    Type: Application
    Filed: December 11, 2014
    Publication date: November 12, 2015
    Applicant: CYTOS BIOTECHNOLOGY AG
    Inventors: MARTIN F. BACHMANN, FRANZISKA LECHNER, TAZIO STORNI
  • Publication number: 20150202281
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: May 30, 2013
    Publication date: July 23, 2015
    Applicants: CYTOS BIOTECHNOLOGY AG, NOVARTIS PHARMA AG
    Inventors: Wolfgang A. RENNER, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Lüönd, Matthias Staufenbiel, Peter Frey
  • Publication number: 20140141036
    Abstract: The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 22, 2014
    Applicant: CYTOS BIOTECHNOLOGY AG
    Inventors: Martin F. Bachmann, Franziska Lechner, Taizo Storni
  • Publication number: 20130315949
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: December 7, 2012
    Publication date: November 28, 2013
    Applicant: Cytos Biotechnology AG
    Inventors: Wolfgang A. RENNER, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Publication number: 20120114674
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 10, 2012
    Applicants: NOVARTIS PHARMA AG, CYTOS BIOTECHNOLOGY AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Lüönd, Matthias Staufenbiel, Peter Frey
  • Publication number: 20110305723
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: December 23, 2010
    Publication date: December 15, 2011
    Applicant: Cytos Biotechnology AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Publication number: 20110293649
    Abstract: The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.
    Type: Application
    Filed: March 19, 2010
    Publication date: December 1, 2011
    Applicant: Cytos Biotechnology AG
    Inventors: Martin F. BACHMANN, Franziska Lechner, Taizo Storni
  • Publication number: 20080274131
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: January 18, 2008
    Publication date: November 6, 2008
    Applicants: Cytos Biotechnology AG, Novartis Pharma AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
  • Patent number: 7320793
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: January 22, 2008
    Assignees: Cytos Biotechnology AG, Novartis Pharma AG
    Inventors: Wolfgang A Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
  • Patent number: 7264810
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: September 4, 2007
    Assignee: Cytos Biotechnology AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Publication number: 20070048287
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: November 3, 2006
    Publication date: March 1, 2007
    Applicant: Cytos Biotechnology AG
    Inventors: Wolfgang Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Publication number: 20060222652
    Abstract: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.
    Type: Application
    Filed: November 10, 2005
    Publication date: October 5, 2006
    Applicant: Cytos Biotechnology AG
    Inventors: Peter Sebbel, Nicolas Dunant, Martin Bachmann, Alain Tissot, Franziska Lechner, Wolfgang Renner, Frank Hennecke, Lars Nieba
  • Patent number: 6964769
    Abstract: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: November 15, 2005
    Assignee: Cytos Biotechnology AG
    Inventors: Peter Sebbel, Nicolas Dunant, Martin Bachmann, Alain Tissot, Franziska Lechner, Wolfgang A. Renner, Frank Hennecke, Lars Nieba
  • Publication number: 20030175711
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: January 18, 2002
    Publication date: September 18, 2003
    Applicant: Cytos Biotechnology AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
  • Publication number: 20030175290
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: January 18, 2002
    Publication date: September 18, 2003
    Applicant: Cytos Biotechnology AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Publication number: 20030091593
    Abstract: The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.
    Type: Application
    Filed: September 16, 2002
    Publication date: May 15, 2003
    Applicant: Cytos Biotechnology AG
    Inventors: Martin F. Bachmann, Franziska Lechner, Tazio Storni
  • Publication number: 20030054010
    Abstract: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.
    Type: Application
    Filed: May 4, 2001
    Publication date: March 20, 2003
    Applicant: Cytos Biotechnology AG
    Inventors: Peter Sebbel, Nicolas Dunant, Martin Bachmann, Alain Tissot, Franziska Lechner, Wolfgang A. Renner, Frank Hennecke, Lars Nieba